ABRA INVEST has collaborated with HEMOSOLVE (exploitation of "sclerosing microfoam" for the treatment of haemorrhoids) through the design of a plan to develop its own clinics and agreements with other prestigious institutions.
History of microfoam sclerosants
In 1993 the Cabrera family invented the sclerosing microfoam. Since then it has been used to treat varicose veins effectively in more than 25,000 patients. As well as being treated in Cabrera's own 5 clinics, the treatment is used under licence by prestigious institutions such as the Clínica Universitaria de Navarra and Sanitas hospitals. Following the success of the microfoam treatment for varicose veins, the inventors have developed microfoam for haemorrhoids.
KEY POINTS:
1. Large size of affected population:
- Outpatient treatment: no need for anaesthesia or surgery.
- No specific post-treatment care and the patient can continue with normal life.
- HEMOSOLVE can cure any type of haemorrhoid. Surgery only for the most acute ones.
- Painless and easily repeatable procedure: The discomfort is similar to a blood draw.
3. Advantageous competitive position:
- The technology is patented and IIDF has authorisation for use in Spain.
- The treatment has been tested in more than 150 patients during 2011 and 2012 demonstrating its efficacy. The Granada Clinic is active.
- Agreements with other institutions underway: agreement with Clínicas Cabrera to offer the treatment, agreement with Médico Digestivo to open a clinic in Madrid, etc.
The team composed of technical staff and professionals with business experience in the healthcare world is well prepared to develop the established business plan.
Diego Gutiérrez Zarza